ライフサイエンスコーパス: cell-free

1 xpressing the individual transporter domains cell-free.

2 cted mutagenesis, molecular modeling, and in cell-free and cell-based systems, we demonstrate that su

3 ue, and green) and under various conditions (cell-free and cell-based, two cell types).

4 d the UL128-131 or RL13 loci.IMPORTANCE Both cell-free and cell-to-cell spread are likely important f

5 at gO diversity can have dramatic impacts on cell-free and cell-to-cell spread as well as on antibody

6 ver, RL13 expression comparably reduced both cell-free and cell-to-cell spread of all three strains,

7 chanistically distinct roles for gH/gL/gO in cell-free and cell-to-cell spread, (ii) gO isoforms can

8 To this end, using both cell-free and cellular experimental systems, including m

9 Here, the cell-free and scalable synthesis of freely suspended and

10 route to fabricating stable DNA nanowires in cell-free and synthetic biological systems for the produ

11 We exploit this cell-free approach to develop tools to probe co-translat

12 eir affinity to PIPs we have developed a new cell free assay based on the ability of the receptor to

13 eased GPX4 activity to 150% at 20 muM in the cell-free assay and 61 muM in cell extracts.

14 red from COVID-19 or vaccine recipients in a cell-free assay system.

15 Here we developed a cell-free assay to recapitulate COPII-dependent budding

16 cysteine mutants continued to bind cargo in cell-free assays and produced an increased level of Erv4

17 itro RNA-binding competition assay, a unique cell-free assembly assay, and an in vivo single-cycle re

18 We apply cell-free biochemical screens to assess the protospacer

19 We use these modules to assemble a cell-free biocircuit that can combine with bacteria-cont

20 Cell-free biology is the activation of biological proces

21 ding the rapid development of whole-cell and cell-free biosensors for various applications in the env

22 These hybrid cell-free biosensors have a fast response time, strong s

23 expand the range of molecules detectable by cell-free biosensors through combining synthetic metabol

24 pression in E. coli and upon purification in cell-free biosynthetic reconstitution reactions.

25 may open diverse applications, ranging from cell-free biotechnology to biomedicine.

26 HIV has been recovered from cell-free bronchoalveolar lavage fluid, alveolar macroph

27 explore a combinatorial space of ~4,000,000 cell-free buffer compositions, maximizing protein produc

28 pidomics of the secretome shed new lights in cell free cancer diagnosis and could be applied as a com

29 m cell-derived human MSCs (hMSCs) (n = 7) or cell-free carrier vehicle (vehicle control; n = 7).

30 t TETRAC promotes PPARgamma/RXR signaling in cell-free, cellular, and in vivo settings.

31 analyses of nucleic acids, including mutant cell-free (cf) DNA in the plasma.

32 a, indicative of mitochondrial function, and cell-free (cf) mtDNA linked to inflammation.

33 d detection of tumor-associated mutations in cell-free circulating DNA often requires the ability to

34 therapies revealed a bimodal distribution of cell-free circulating tumor DNA (ctDNA) after therapy in

35 on ENS of man-made (synthetic) molecules in cell-free conditions, classified by the types of enzymes

36 erent processing methods for the creation of cell-free constructs resulting in preservation of the ex

37 d in a 50% increase in perfusion compared to cell-free control.

38 Detection of cell-free CSF HIV RNA was associated with higher plasma

39 Here, we show that cell-free culture fluids from the marine bacterium Vibri

40 Using host cell-free culture, progesterone was determined to have a

41 Using a cell-free degradation assay, ABA promoted degradation of

42 Cell-free deoxyribonucleic acid (cfDNA) released from ei

43 ing and whole-genome bisulfite sequencing of cell free DNA (cfDNA) and of matched metastatic tumor bi

44 However, the plasma cell free DNA (cfDNA) level can be low and the fraction

45 1047R) in circulating tumor cells (CTCs) and cell free DNA (cfDNA).

46 lood or urine and sequencing the circulating cell free DNA (cfDNA).

47 methylcytosine (5hmC) changes in circulating cell free DNA from a PDAC cohort (n = 64) in comparison

48 ed that pristane-injected mice had increased cell free DNA in serum, which was not impacted by inhibi

49 the utility of high-throughput sequencing of cell-free DNA (cfDNA) after bisulfite conversion to map

50 unities for detection of residual disease in cell-free DNA (cfDNA) after surgery but may be confounde

51 ging technologies are reliant on circulating cell-free DNA (cfDNA) and cell-free RNA (cfRNA) applicat

52 Diagnostically informative microbial cell-free DNA (cfDNA) can be detected from blood plasma

53 Elevation of circulating cell-free DNA (cfDNA) concentration has been shown to be

54 Cell-free DNA (cfDNA) extracted from maternal plasma was

55 Disease diagnosis using cell-free DNA (cfDNA) has been an active research field

56 measured by (18)F-FDG PET/CT and circulating cell-free DNA (cfDNA) have been separately validated as

57 hat detection of Borrelia burgdorferi (B.b.) cell-free DNA (cfDNA) in plasma can improve diagnosis of

58 Measuring the methylation status of cell-free DNA (cfDNA) in plasma holds great potential fo

59 next-generation sequencing (mNGS) of plasma cell-free DNA (cfDNA) is commercially available, but its

60 hat the majority of somatic mutations in the cell-free DNA (cfDNA) of patients with lung cancer and o

61 Although cell-free DNA (cfDNA) shows promise in detecting cancer

62 genetic mutants (EGFR T790M) with precision cell-free DNA (cfDNA) standards.

63 suggested that liquid biopsy (specifically, cell-free DNA (cfDNA)) may better capture the heterogene

64 le-nucleotide variants (SNVs) in circulating cell-free DNA (cfDNA), a mixture of DNA molecules origin

65 omarkers, circulating tumor cells (CTCs) and cell-free DNA (cfDNA), with regard to pancreatic ductal

66 ay to identify patients with RCC using urine cell-free DNA (cfDNA; AUROC of 0.86).

67 Donor-derived cell-free DNA (dd-cfDNA) in the blood circulation is an

68 sing marker is the presence of donor-derived cell-free DNA (dd-cfDNA) in the urine or blood of transp

69 Donor-derived cell-free DNA (dd-cfDNA) is an important molecular marke

70 ods present an opportunity for donor-derived cell-free DNA (dd-cfDNA), which can accurately and rapid

71 Pathogen cell-free DNA (pcfDNA) in blood and urine is an attracti

72 Combining our approach with mutation-based cell-free DNA analyses detected 91% of patients with can

73 ome sequencing of post-mortem plasma-derived cell-free DNA and eight frozen metastatic cancer tissues

74 ics of the origins and molecular features of cell-free DNA are poorly understood.

75 Plasma cell-free DNA at baseline showed ERBB2 (HER2) amplificat

76 ian proportion of tumor-derived DNA in total cell-free DNA before treatment was 0.07%, indicating tha

77 p Sequencing, [CAPP-Seq]) analyses of plasma cell-free DNA collected from 45 patients before and afte

78 ole genome DNA lysed from cell line and from cell-free DNA collected from cell culture media.

79 sma DNA fragmentomics is an emerging area in cell-free DNA diagnostics and research.

80 durable responses occurred in patients with cell-free DNA ERBB2 amplification.

81 nfers accessibility of TF binding sites from cell-free DNA fragmentation patterns.

82 Liquid biopsy analysis of circulating cell-free DNA fragments in the patients' blood can monit

83 next-generation sequencing (mNGS) test using cell-free DNA from body fluids to identify pathogens.

84 ve, as well as single genetic loci from pure cell-free DNA from peripheral blood.

85 LINE-1 hypomethylation of cell-free DNA has been described as an epigenetic biomar

86 ted methods, sequencing identified microbial cell-free DNA in 62, likely derived from commensal organ

87 In an analysis of cell-free DNA in blood samples from patients who underwe

88 redictive impact of ultra-deep sequencing of cell-free DNA in patients before and after cystectomy an

89 est that identifies and quantifies microbial cell-free DNA in plasma from 1,250 clinically relevant b

90 Cell-free DNA in the blood provides a non-invasive diagn

91 Cell-free DNA is a promising biomarker for monitoring th

92 Cell-free DNA is present in different biological fluids

93 ficient differentiation between cellular and cell-free DNA may have confounded analyses of genome-wid

94 lecular diagnostics based on the analysis of cell-free DNA or single-nucleotide variants (SNVs) out o

95 To achieve this, we performed cell-free DNA quantification and characterization assays

96 lyze whole genome sequencing data for >1,000 cell-free DNA samples from cancer patients and healthy c

97 Furthermore, post-mortem plasma cell-free DNA sequencing (liquid autopsy) can be a novel

98 luated the performance of a plasma microbial cell-free DNA sequencing (mcfDNA-Seq) test for diagnosin

99 Molecular response measured by cell-free DNA sequencing at day 7 after infusion was sig

100 Microbial cell-free DNA sequencing offers the potential to non-inv

101 Furthermore, we show that cell-free DNA TF profiling is capable of detection of ea

102 ed a blood-based biomarker assay using tumor cell-free DNA to measure systemic tumor burden longitudi

103 Therefore, tumor cell-free DNA was capable of altering the receptor cell

104 points within the 28-day observation period, cell-free DNA was isolated and analyzed by next-generati

105 The post-mortem plasma cell-free DNA was successfully sequenced and 344 mutatio

106 rst confirmed that substantial quantities of cell-free DNA were present in the post-mortem plasma of

107 oRNA, circulating tumor cells, exosomes, and cell-free DNA, and discuss the opportunity of utilizing

108 uding changes in circulating microparticles, cell-free DNA, and neutrophil extracellular traps.

109 (V600E) allele load, assessed as circulating cell-free DNA, decreased after starting VMF but remained

110 hus, this study analyzed the effect of tumor cell-free DNA, isolated from the blood of prostate cance

111 Detection of actionable drug targets in cell-free DNA, more comprehensive molecular profiling in

112 d mortality, whereas other NET assays (e.g., cell-free DNA, myeloperoxidase, and myeloperoxidase-DNA

113 overy tool for fragmentation analyses and in cell-free DNA.

114 r for mono- and bis-phosphorylated PIPs in a cell free environment.

115 Here we develop a flexible cell-free enzymatic prenylating system that generates is

116 However, because cell-free enzyme synthesis requires a considerable amoun

117 Cell-free eosinophil granules are found in tissues in eo

118 Cell-free EV preparations were toxic to mammalian cells,

119 In cell-free experiments, recombinant TTP lacking its CNBD

120 HIV or concentrated, immobilized HIV-ICs in cell-free experiments.

121 e 1-methyl-4-phenylpyridinium(+) (MPP(+)) by cell-free-expressed fusion proteins of rOCT1 and rOCT1 m

122 rrestin-bound states of Y2R were prepared by cell-free expression, functional refolding, and reconsti

123 ening in water-in-oil emulsion droplets with cell-free expression.

124 Cell suspension and cell free extract experiments with strain UNSWDHB were b

125 as can be a good alternative to conventional cell-free extract based methods.

126 l scavenging potential than the conventional cell-free extract method.

127 Pulldown experiments with K. stuttgartiensis cell-free extract showed that the KsNaxLS complex binds

128 assays were lower than those of conventional cell-free extract-based methods.

129 Both intact cells (IC) and intracellular cell-free extracts (CFE) from most of the strains exhibi

130 Here, we used cell-free extracts derived from Xenopus laevis eggs to r

131 Using recombinant VdtB and VdtD as cell-free extracts from A. nidulans, we demonstrated tha

132 ding was confirmed by in vitro NER assays in cell-free extracts from human HeLa cells, suggesting tha

133 ophenol (DCPIP) reduction is not detected in cell-free extracts from wild-type strain methanol- and l

134 In cell-free extracts of Xenopus laevis eggs, we find that

135 on of an experimental approach that combines cell-free extracts with photo-patterned hydrogel micro-e

136 ral recombinants is replication competent in cell-free extracts, in yeast, and in the plant Nicotiana

137 ompounds in various leaf discs suspended and cell-free extracts.

138 s, genetically in cells and enzymatically in cell-free extracts.

139 most same phytochemical profiles to those of cell-free extracts.

140 rential utilization of polyphosphates in the cell-free exudates of Thalassiosira spp., and suggest th

141 tal brain hypoxia, and increased circulating cell free fetal DNA and soluble Flt1.

142 Furthermore, cell-free filtrates of some isolates produced Mn oxides

143 r inflammatory gene expression profiles, and cell-free fluid was assayed for cytokines.

144 Both whole-cell and cell-free formats were investigated to assess key sensin

145 Cell-free gene expression followed by mass spectrometry

146 high-yielding (grams of protein per litre), cell-free gene expression systems from model bacteria, t

147 t permits expanded multiplexed reporting for cell-free gene-circuit-based sensors.

148 brane integrity, cell death, and presence of cell-free granules.

149 g haptoglobin therapeutics to target 'toxic' cell-free Hb exposures.

150 oxide bioavailability due to the presence of cell-free hemoglobin (CFH) increases vascular tone in se

151 Hemolysis and accumulation of cell-free hemoglobin (Hb) in the circulation or in confi

152 erythrocytes to prevent the toxic effects of cell-free hemoglobin and heme.

153 Cell-free hemoglobin that is released from erythrocytes

154 We established a cell-free high-throughput screening assay to search for

155 CD4-MBL CAR-T cells were unresponsive to cell-free HIV or concentrated, immobilized HIV-ICs in ce

156 everse transcriptase) regions amplified from cell-free HIV RNA in blood and seminal plasma using the

157 In CSF supernatant and blood plasma, cell-free HIV RNA was quantified by qPCR with single cop

158 1 DNA (P = .003), but less so with inducible cell-free HIV-1 RNA (P = .09).

159 Inducible cell-free HIV-1 RNA correlated with HIV-1 DNA, most part

160 pheral blood mononuclear cells and inducible cell-free HIV-1 RNA in CD4+ T-cells by a prostratin anal

161 HIV-1 DNA, inducible cell-free HIV-1 RNA, and S/COs correlated directly with

162 These findings suggest that spliced or cell-free HIV-1 RNAs are more indicative of antigen expr

163 We report the development of a cell-free in vitro transcription system that uses RNA Ou

164 Receptor function of EphA7 was conserved for cell-free infection by the related rhesus monkey rhadino

165 d to here as ADgO(GT1a)] drastically reduced cell-free infectivity of both strains on fibroblasts and

166 PHgO(GT2a) increased cell-free infectivity of TR in both cell types, but spre

167 nced by Towne (TN) gO (GT4), despite similar cell-free infectivity.

168 greement with the in vitro findings on human cells, free ISG15 boosted the CTL response in vivo via N

169 os, a decrease was observed in the red blood cell-free layer and platelet margination due to an incre

170 We find a cell-free layer development length greater than 46 and 2

171 By analyzing the RBC migration and cell-free layer development within a high-aspect-ratio c

172 signal transduction by CARs, we developed a cell-free, ligand-based activation and ex vivo culture s

173 vents and was even observed in reconstituted cell-free liposomes.

174 l spread, forcing the virus to transmit in a cell-free manner.

175 at hNSC process outgrowth and migration into cell-free matrix and into astrocyte-containing matrix ar

176 In contrast, infectious cell-free MDV is produced in specialized feather follicl

177 Cell-free methods may provide a powerful alternative to

178 Cell-free methylated DNA immunoprecipitation and high-th

179 The aim of this study is to identify cell-free micro ribonucleic acid (miRNA) biomarkers in g

180 mples in total) solely using plasma-derived, cell-free microbial nucleic acids.

181 study is required to confirm the utility of cell-free miR-505-3p as prognostic biomarker for DGF.

182 n MVs, and their relationship to circulating cell-free mitochondrial DNA (ccf-mtDNA) in HIV-infected

183 Likewise, circulating, cell-free mitochondrial DNA (ccf-mtDNA) is under similar

184 Here we show that cell-free mitochondrial DNA (cf-mt-DNA) released by sene

185 Cell-free mitochondrial DNA (cfmtDNA) is detectable in a

186 es membrane tethering and hemifusion in this cell-free model.

187 Circulating cell-free mRNA (cf-mRNA) holds great promise as a non-in

188 By contrast, circulating cell-free mtDNA concentrations in unaffected heterozygou

189 ted IL6, C-reactive protein, and circulating cell-free mtDNA in serum of 245 participants in two coho

190 However, the role of IL6 and circulating cell-free mtDNA in unaffected and affected individuals h

191 to control levels; and (iv) that circulating cell-free mtDNA levels have good predictive potential to

192 mutations in PRKN/PINK1, IL6 and circulating cell-free mtDNA levels may serve as markers of Parkinson

193 PINK1 mutations; (iii) increased circulating cell-free mtDNA serum levels in both patients with biall

194 Here we present a modular, cell-free multienzymatic platform to access these struct

195 Progress in the study of circulating, cell-free nuclear DNA (ccf-nDNA) in cancer detection has

196 lection of circulating tumor markers such as cell-free nucleic acids and circulating tumor cells in t

197 Detection of disease-associated, cell-free nucleic acids in body fluids enables early dia

198 ned by filtering ultrasmall Saccharibacteria cells free of other larger bacteria and inoculating them

199 strains can be highly specialized to either cell-free or cell-to-cell mechanisms, and this was not s

200 ention strategies for their ability to limit cell-free or cell-to-cell spread as independent processe

201 ins can be highly specialized for either for cell-free or cell-to-cell spread, and these phenotypes a

202 cells, despite exhibiting severe defects in cell-free particle infectivity and Env-mediated fusogeni

203 -type (WT) and mutant human CFTR channels in cell-free patches of membrane.

204 Additionally, CSMD applied to cell-free plasma DNA showed that microbial diversity wit

205 tems from model bacteria, the development of cell-free platforms from non-model organisms and multipl

206 uding Dicer and Argonaute-2, which allow for cell-free pre-miRNA processing within shed vesicles.

207 s could be a potential alternative source of cell-free product for attenuation of aging-related skin

208 identifying critical parameters involved in cell-free productivity.

209 Cell-free products of HMN sputum microbiota induced feat

210 this gap by combining Escherichia coli-based cell-free protein synthesis (CFPS) and self-assembled mo

211 ombination of single-molecule techniques and cell-free protein synthesis.

212 We used a cell-free reaction that reproduces a key autophagy initi

213 Furthermore, we manipulate the cell-free reaction to pause and re-start protein synthes

214 pus La and sorting into vesicles formed in a cell-free reaction.

215 Integrating SNIPRs with portable paper-based cell-free reactions enables convenient isothermal detect

216 nsitive channel of large conductance, during cell-free reactions when vesicles containing diblock cop

217 gy to control the spatiotemporal dynamics of cell-free reactions, expanding opportunities to engineer

218 Whereas cell-free reconstituted biopolymer networks typically so

219 Here, we accomplished a cell-free reconstitution of the sphingolipid regulation

220 Using a cell-free reconstitution system, we report that clathrin

221 f LegC8 effector on TBSV replication using a cell-free replicase reconstitution assay.

222 ole for Sac1 in TBSV replicase assembly in a cell-free replicase reconstitution assay.

223 M and N'/N, the RNAp/NTPs machinery, and the cell-free ribosome t-RNA machinery leads to the CDNs-gui

224 wo and three dimensions by modeling producer cell, free-rider cell and public good densities in space

225 ant on circulating cell-free DNA (cfDNA) and cell-free RNA (cfRNA) applications in the clinic.

226 s, and found that circCNOT2 is detectable in cell-free RNA from plasma.

227 ith high cells/beads utilization efficiency, cell-free RNAs removal capability, high gene detection a

228 es and pumps enables the complete removal of cell-free RNAs, efficient cell lysis and mRNA capture, a

229 techniques prior to butanol determination in cell-free samples from an anaerobic butanol fermentation

230 strains clearly differ in their capacity for cell-free spread as a result of differences in the quant

231 ndicating that ME is not simply deficient at cell-free spread but is particularly efficient at cell-t

232 ed" phenotypes are simply the result of poor cell-free spread or are indicative of particularly effic

233 arise in culture lead to the appearance of a cell-free spread phenotype.

234 is was not strictly linked the efficiency of cell-free spread.

235 rotein will block cell fusion, again forcing cell-free spread.

236 Likewise, CFE and intracellular cell-free supernatants (CFS) exhibited potential inhibit

237 The objectives of this study were to assess cell-free supernatants (CFS) of 16 strains of these bact

238 we detected RNase 3, RNase 6, and RNase 7 in cell-free supernatants and viable cells obtained from pe

239 for GLP-1 modulation by incubating bacterial cell-free supernatants with NCI H716 L-cells.

240 Here we address this challenge by combining cell-free synthesis and assembly of translationally comp

241 Cell-free synthesis, although not practically amenable f

242 athways are assembled by mixing-and-matching cell-free synthesized glycosyltransferases that can elab

243 unleash its great potential in accelerating cell-free synthetic biology.

244 alpha-galactose adjuvant motif in a one-pot cell-free system and human antibody constant regions wit

245 DNA- and RNA-based, C-Ag(+)-C duplexes in a cell-free system have been constructed in an Escherichia

246 Here, we report a cell-free system in a bioreactor with continuous product

247 Here, we used a cell-free system in combination with a high-throughput m

248 peptides of various activating potency in a cell-free system in the force range (6 to 15 pN) previou

249 The resultant feedback generates a cell-free system that can synthesize fluorescent reporte

250 Using purified proteins, we report a minimal cell-free system that demonstrates interdomain cooperati

251 Here, we use a cell-free system to show that ANKZF1 and Vms1p sever pol

252 Together, these results establish a new cell-free system to study the regulation, initiation, an

253 d the early stages of HIV-1 replication in a cell-free system.

254 iviral activity and cleaved by MCPIP1 in the cell-free system.

255 sembly of a collided polysome in a mammalian cell-free system.

256 thetic biology concept to the engineering of cell-free systems by exploiting the crosstalk between me

257 Lysate-based cell-free systems have become a major platform to study

258 Here, using newly developed human cell-free systems that recapitulate distinct inter-mitot

259 exed DNA/RNA cleavage and gene regulation in cell-free systems, bacteria, and yeast.

260 ally do not exhibit constitutive activity in cell-free systems, leading to the suggestion that in int

261 ated from experiments in cell-based systems, cell-free systems, mouse and lower organism models of di

262 ed tools, implemented in both whole-cell and cell-free systems.

263 -fold higher expression level than classical cell-free systems.

264 MSC secretome or its components as potential cell-free therapeutic products.

265 an cells into immortal exosome factories for cell-free therapies.

266 on of isolated TGNC and may be considered as cell-free therapy for TG nerve repair.

267 the EV-released KMP2 hydrogel is a promising cell-free therapy for tissue repair.

268 Cell-free transcription-translation (TXTL) is expanding

269 Whole-cell and cell-free transcription-translation biosensors have rece

270 Executing gene circuits by cell-free transcription-translation into cell-sized comp

271 ic RNA detection capabilities in vivo and in cell-free transcription-translation reactions.

272 lement the controller in an Escherichia coli cell-free transcription-translation system, which allows

273 Here, we used cell-free transcription-translation systems and human ce

274 Cell-free transcription-translation systems have great p

275 Cell-free translation assays with humanized bacterial ri

276 effective in this respect through the use of cell-free translation assays with wild-type bacterial an

277 Cell-free translation assays, quantitative ribosome foot

278 Cell-free translation offers opportunities to remedy thi

279 eral applicability of this assay to distinct cell-free translation systems by using extracts prepared

280 F (ranging from 0.1-100 ng/muL) expressed in cell-free translation systems.

281 levels as high as 58% in rabbit reticulocyte cell-free translations and 81% during virus infection.

282 lls, and pave the way for stem cell-inspired cell-free treatments of cardiac and other injuries.

283 t to meet the requirements for point-of-care cell-free tumor DNA (ctDNA) and microRNA (miRNA) detecti

284 rs responsible for the low detection rate of cell-free tumor DNA (ctDNA) in the plasma of patients wi

285 ital PCR make detection of minor circulating cell-free tumor DNA amounts in blood from cancer patient

286 n show that detectable levels of circulating cell-free tumor DNA correlate with clinical development

287 Increasing levels of circulating cell-free tumor DNA during melanoma treatment with eithe

288 a time course of the quantified circulating cell-free tumor DNA.

289 evelopment of new therapeutics.Significance: Cell-free tumor load provides a novel approach for evalu

290 have developed an ultrasensitive measure of cell-free tumor load using targeted and whole-genome seq

291 s currently measured on two commercial-grade cell-free tumour DNA platforms, despite the use of very

292 MDV-infected cells do not produce infectious cell-free virus in vitro, raising the question about the

293 d to uninfected cells by two main routes: by cell-free virus or by cell-to-cell spread.

294 infected cells far more efficiently than by cell-free virus.

295 reduces initial infection of macrophages by cell-free virus.

296 ted virus and 3- to 6.2-fold-lower growth of cell-free virus.

297 ction by contact with infected cells than by cell-free virus.

298 letion profoundly impaired the production of cell-free viruses during PCV2 infection.

299 st analysis and comparative activity data, a cell-free workflow using synthetic DNA minicircles and r

300 abeling of transient protein interactions in cell-free Xenopus laevis egg extract identified the dime